Intruduction
The role of allergen specific IgG in allergic inflammation is still unclear. Allergen specific IgG is reported to be predominated by IgGl and IgG4 antibodies [1] [2] [3] [4] . Conflicting results were found in examining the role of IgG in the allergic reaction. Some investigators found evidence for an anaphylactic role for allergen specific IgG, e.g. IgG4 |5-7|. These results could not be reproduced by others 18] . On the other hand, allergen specific ]gG4 might be protective, working as a blocking antibody. Inhibitory effects of Correspondence: R. C. Aalberse, Department of Allergy, Central Laboralor>' ol' ihe Red Cross Blood Transfusion Service. Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands. allergen specific IgG antibodies, were shown in histamine release experiments [9] [10] [11] [12] [13] [14] in skin-prick tests 11, [15] [16] [17] and in vivo 118].
Prolonged immunization, as in allergen immunotherapy, leads to the development of allergen specific lgG4 antibodies [1.3.19] . Although a correlation of IgG4 titres with clinical outcome of the immunotherapy was not always found [4|. allergen specific IgG4 antibodies might effect clinical improvement [19, [20] [21] [22] . and the development of these antibodies is often monitored during immunotherapy. To achieve inhibition of the allergic reaction the amount of allergen specific (blocking) IgG compared to the amount of allergen specific IgE is of interest [17] : the molar ratio IgE/ IgG is of importance. 1997 Blackwell Science Ltd Previously we reported on a chimeric IgE antiDer p 2 antibody (hIgE-Dp2 A) [23, 24] and discussed the use of this antibody for the absolute quantification of allergen specific IgE. We now report on the construction of mouse/ human chimeric monoclonal IgGl and IgG4 antibodies by recombinant DNA techniques from a mouse monoclonal antibody directed to Der p 2. a 14 kDa monomeric allergen [251. These chimeric antibodies have the binding characteristics of the original mouse monoclonal antibody 2B12 |26]. whereas the Fc-domain is derived from human IgG I or IgG4. More precisely, these chimeric antibodies consist of the heavy chain variable domains and the complete light chains from the mouse hybridoma. whereas the constant domains of the heavy chain are of human origin.
Since ail IgG in these culture supernatants is allergen specific, they are useful reference reagents and enable the calculation of the absolute amount of allergen specific IgGl and IgG4 antibodies.
Materials and methods

Hybridoma cell line
Monoclonal antibody against Der p 2. 2B12, subclone B3 (mouse lgG2b with kappa light chains), has been described previously |26|.
Culture conditions
The 2B12 hybridoma cells, the heavy chain loss variants and the transfectomas were cultured in IMDM (GIBCO/BRL. Paisley. Scotland) containing 5% heat-inactivated FCS (Bodinco, Alkmaar. The Netherlands). 50/xM 2-mercaptoethanol. penicillin (lOOIU/niL), streptomycin (lOO/xg/mL) and rhIL6 (500 U/mL [27] ).
Selective medium was supplemented with 500/xg Geneticin base/mL (Sigma Chemicals Co.. St. Louis. MO. USA). Transfectomas were grown in 1 L rollerbottles (Falcon, Becton Dickinson Labware. New Jersey, USA) in culture medium without G4I8. The culture supematants obtained were concentrated (approximately five times) using a hollow fibre dialyser (Hemoflow F5. Fresenius AG. Bad Homburg, Germany).
Sera
Sera of mite allergic patients G and H, receiving mite specific immunotherapy {Dermatophagoides pteronyssinus extract. ALK. Denmark) 100000 SQ per immunization. The sera were drawn before starting the immunotherapy and during therapy.
Mouse/human chimeric IgE. IgGl and lgG4 monoctonat antibodies {hlgE-Dp2 A. hlgGIDp2 A and hIgG4-Dp2 A) derived from monoctonat antibody 26/2
The development of hIgH-Dp2 A was reported previously 123.24]. The chimeric Dp2 A IgGl and IgG4 antibodies were prepared by combining methods described previously [23.24.28-30|. Briefly: a heavy chain expression plasmjd was prepared as follows. RNA was isolated from 10^ 2B12 hybridoma cells, and cDNA was prepared using a RT-H-kit (GIBCO/BRL) in combination with an oligo-dT primer (Boehringer, Mannheim. Germany).
The 2B12 Vn domain was then amplified in a polymerase chain reaction (PCR) using V].|-domain specific primers. [ 31 ] with minor modifications), which contained restriction enzyme recognition sequences used in cloning as described below. Restriction sites for Hindlll. Bsu36I and PstI are underlined in the primer sequence. Restriction endonucleases were obtained from GIBCO/BRL except for Bsu36I which was obtained from New England Biolabs (Beverly. MA. USA). Plasmid isolations, restriction enzyme digestions and agarose gel electrophoresis were performed as described in Sambrook et at. [32] . DNA sequence analysis of the Vn-domain was performed using Sequenase according to the manufacturers suggested conditions (USB, Cleveland. OH, USA).
The heavy chain construct was prepared in the vector pSV-SPORT (GIBCO/BRL) and contained the IgH intron enhancer. IgH promoter, IgH leader sequence, VH-2B12 domain, and intron fragment [29.30] . For IgGl and IgG4 constructs a human genomic C7I-or C74-gene (Hindlllfragments) I29,33]was introduced in the unique Hindlll site.
Several heavy chain loss variants (secreting light chains only) were isolated from a population of 2BI2 hybridoma cells which was cultured for a period of 6 month during which the cells were transferred 2-3 times per week 130.34]. This population of cells was further enriched for clones producing light chains only by sorting for heavy chain negative clones on a FACS using an antimouse IgG2b FITC-labelied antibody (RM 162b-MF, CLB, Amsterdam, The Netherlands). Hybridoma eells producing light chains but not heavy chains were then identified in ELISA \?i5\. Production of light chains only was confirmed in biosynthetical labelling with ^^S-methionine and analysis on SDS-PAGF.
Heavy chain plasmid was introduced in a heavy chain loss variant by cotransfection with pSV2-neo [36] . Heavy chain The cells were plated in two 48-wells culture plates (Costar. Cambridge. MA. USA) in culture medium. Selective medium containing 500 ^g Genetiein base/mL was added after two days. Clones were screened for hIgGI and hIgG4 production and for binding to mite extract coupled to Sepharose in RAST (as described below). Mite-positive clones (transfectomas) were subcloned by limiting dilution. 
Radio Immuno Assays
Der p 2
Recombinant Der p 2 [37] was used. The insert Der p 2 was cloned in the vector pET-21a (Novagen, Madison, WI, USA) and expressed in E. coli BL21-pLysE (Novagen). Der p 2 was purified by affinity chromatography using monoclonal antibody aDpX [38] .
Der Per test 50 ^L chimeric antibody or human serum dilution was added to Sepharose coupled allergen. Human sera were obtained from the Allergy diagnostics department from the CLB (Amsterdam, The Netherlands).
Detection was performed using '^''I-Iabelled sheep antibodies to human IgE, ''^''I-labelled anti-IgGI antibodies (MH161-1M, CLB) or '^^I-labelled anti-IgG4 (MHI64-1 M, CLB) antibodies, respectively. The IgE-RAST was described previously [39] , the IgGi and IgG4-RAST were described previously [1, 40] . The results were expressed as the amount of radioactive label bound relative to the total amounts of radioactivity added. When the concentration of allergen specific antibodies was calculated the serum dilution resulting in about 20% of binding was used (the steepest part of the dose-response eurve).
Mite RIA. detection with antilight chain antibodies
Mite Sepharose (1.5 mg in 250/xL) was incubated with 50 ^L antibody dilution. Detection was perfonned using '"^I-labelled rat anti(mou.se) kappa light chain antibodies (RM 19, CLB) making use of the identical mouse light chain of the chimerie hIgE-Dp2 A. hIgGl-Dp2 A and hIgG4-Dp2 A. The supernatants of the hIgGl-Dp2 A and hIgG4-Dp2 A transfeetomas were quantified by this assay using hlgE-Dp2 A [23,24| as a reference reagent.
Reversed RAST
Chimeric antibody dilutions or diluted serum samples (50;uL per ineubation) were incubated with 1 mg anti-lgG4-Sepharose (MH164-1 M. CLB. Am.sterdam, 1 mg antibody was eoupled to lOOmg CNBr-activated Sepharose 4B) in 500 AtL. The binding of '"^I-reeombinant Der p 2 (iodination of Der p 2 is described below) was measured. The results were expressed as the amount of radioactive label bound relative to the total amounts of radioactivity added.
Iodination of Der p 2
Der p 2 was iodinated by the chloramine T method with carrier-free '"^I (Amersham. UK) as was deseribed for PLA2 |3| with minor modifications: l-propanol was added to Der p 2 (20 /ig in PBS) to a final concentration of 30% (v/v) prior to labelling. The labelling was performed with I mCi of '' I. Eree label was separated from '"''I-recombinant Der p 2 by dialysis to PBS containing 0.01% (w/v) PEG-4000.
Results
Expression of mouse/human chimeric hlgGi-Dp2 A and hlgG4-Dp2 A monoclonal antibodies
Previously, we deseribed mouse/human chimeric IgE antibodies. hIgE-Dp2 A, directed against the house dust mite allergen Der p 2 [23, 24] . By the same method also chimeric hIgGl-Dp2 A and hIgG4-Dp2 A were prepared. These isotypic variants have the same antigen binding specificity and differ only in their constant domains of the heavy chain. Culture supernatant dilutions of the transfeetomas were tested in their binding to mite-extract using an IgGl and IgG4 Der p 2 RAST (Fig. I) . Also the binding of hIgE-Dp2 A is shown in this figure. Radiolabelled anti-IgGl, anti-lgG4 and anti-IgE were used as tracer. As expected when different labelled antibodies arc used, the dose response curves of these three assays are not parallel and the maximal binding differs.
Comparison of hlgE-Dp2 A. hlgGl-Dp2 A and hIgG4-Dp2 A
The binding of the chimeric hIgGl-Dp2 A and hIgG4-Dp2 A antibodies to mite-Sepharose was eomparcd with hlgE-Dp2 A using an antibody directed to the light chains of the chimerie antiDer p 2 antibodies. The light chains of the different isotypes of Dp2 A are identical and derived from the original mouse monoelonal antibody 2B12. Through this method the culture supernatants were calibrated using chimeric hIgE-Dp2 A as a reference reagent. Eigure 2 shows the binding of the culture supernatant of hlgGl-Dp2 A and hIgG4-Dp2 A to mite-Sepharose. Also the dose response curve of chimeric hlgE-Dp2 A is shown. These dose-response curves were parallel, doubling the antibody coneentration resulted in an increase of 14.4% binding of the labelled antilight chain antibodies (expressed as percentage binding of the total amount of label added). The five times concentrated culture supernatant of hIgGl-Dp2 A and hIgG4-Dp2 A transfeetomas contained 5 and 17 figlmL. respectively.
Calibration of the amount of allergen specific IgE, IgGl and IgG4 antibodies
Sera of mite allergic patients receiving allergen specific immunotherapy were evaluated for their amount of Der p 2 specific IgE, IgGl and IgG4 antibodies expressed in ng/mE. Two panels of sera, from patient G and H, drawn before starting the immunotherapy and during therapy, were tested for IgE. IgGl and IgG4 Der p 2-RAST and in reversed RAST for IgG4 with radiolabelled Der p 2. The chimeric hIgE-Dp2 A. hIgGl-Dp2 A and hIgG4-Dp2 A were used as reference reagents. No Der p 2 specific IgGl was detected (i.e. levels were < 30 ng/mL) in these sera. In Eigs 3 and 4 the IgG4 RAST and IgG4 reversed RAST with radiolabelled Der p 2 for two sera of each patient are shown. None of the tested sera showed detectable binding to control Sepharose (i.e. binding < 1.4% of added radioactivity, data not shown). The dose-response curves of hIgG4-Dp2 A was compared with the dose-response curves of IgG4-Der p 2 positive sera. In the steepest part of the dose-response curve of hIgG4-Dp2 A, shown in Fig. ^, doubling the antibody concentration led to an increase of 7.6% binding of the anti-lgG4 label (expressed as percentage binding of the total amount of anti-IgG4 label added). The patient sera tested showed an increase of 6.1 ± 1.4 (SD. n -5)% binding. Eor the reversed IgG4-RAST with radiolabelled Der p 2, Fig. 4 , not all the dose response curves of the sera were parallel with hIgG4-Dp2 A. This might be a result of the few serum dilutions tested in this assay. Doubling the hIgG4-Dp2 A antibody concentration led to an increase of 9.5% binding. When the IgG4 RAST and IgG4 reversed RAST were compared, the reversed IgG4 RAST seemed to be slightly less sensitive than the IgG4 RAST in the determination of the amount of Der p 2 specific IgG4 (Fig. 5 ). Figure 6 shows the different sera of the two patients G and H and their amount of Der p 2 specific IgE and IgG4 antibodies tested in RAST at the different moments after the statt of the immunotherapeulic treatment. These Der p 2-RAST data indicated for both sera panels an increase in the amount of Der p 2 specific IgG4 to about 10-100 times the amount of allergen specific IgE during the ongoing immunotherapeutic treatment.
The decrease of the titre of Der p 2 specific IgE in both patients could be an attifact due to competition of the increased amount of Der p 2 specific IgG4 antibodies. However, addition of lOOOng/mL hlgG4-Dp2 A did not influence the binding of higE-Dp2 A to mite-Sepharose. The binding of 1.75, 3.5 or 7 ng/mL hIgE-Dp2 A to mite extract coupled to Sepharose was 5.1%, 8.0% or 12.5%. respectively (detected with radiolabelled antilgE antibodies). After addition of 1000 ng/mL hlgG4 the binding was 4.8%, 8.0% or 13.5%. respectively.
Discussion
Immunotherapy is known to induce a rise in allergen specific IgG4 antibodies. This increase is often monitored during immunotherapy and may be linked to clinical improvement [19-22J. The scope of this paper is to show that using a reference chimeric antibody reagent the amount of allergen specific antibodies can be calculated. Usually the amount of allergen specific IgG is expressed in arbitrary units. Expression of the amount of allergen specific IgG. as well as that of allergen specific IgE. iti absolute amounts of protein was illustrated by using h[gGl-Dp2 A and hIgG4-Dp2 A as reference reagent. Two panels of sera collected during immunotherapeutical treatment were examined. These sera contained low amounts of Der p 2 specific IgGl antibodies (all below the limit of detection). This was unexpected since allergen specific IgG antibodies are reported to be predominantly of the IgGl and IgG4 subclass [1-4|. However, sera of only two patients were tested for Der p 2 specificity. Also patients treated with dog-dander immunotherapy showed a failure of the IgGl specific response 116]. The calibration of Der p 2 specific IgG4 antibodies in these sera was performed in two different assays. The two assays used, the Der p 2-RAST ( Fig. 3 ) and reversed RAST with radiolabelled Der p 2 (Eig. 4) using hIgG4-Dp2 A as reference reagent, were comparable for IgG4 calibration {Eig. 5): the amount of Der p 2 specific lgG4 measured was almost similar in both assays. Comparing the hIgG4-Dp2 A dose response curves in these two assays, the reversed RAST was slightly more sensitive than the Der p 2 RAST (data not shown). However, this is not true for every allergen and is dependent of the quality of labelled tracer also. The use of reversed RAST in the measuring allergen specific IgG antibodies has some disadvantages compared to RAST. The reversed RAST is more sensitive to allergenantibody avidity differences, purified and labelled allergens are necessary. Eor each allergen another allergen specific reference reagent is needed. Testing of allergen specific IgG in RAST is less dependent on avidity, however, allergen excess conditions are necessary for a realistic quantification (also discussed in [24] ). The efficiency of the allergosorbent to extract allergen specific antibodies from the serum sample is influenced by the avidity of the antibody-allergen interaction. When the amount of ailergosorbent is added in excess these complications can be circumvented. Re-testing of the serum sample after the first incubation, or testing of the variability in binding when a twofold variation of allergosorbent dose is used will give information about the amount of allergosorbent needed. Furthermore testing in RAST enables the calibration of all the allergen specific assays with one reference reagent and one tracer (directed to the heavy chain).
The role of allergen specific IgG4 in the clinical improvement of allergic patients remains unclear. Eor a blocking effect of allergen specific IgG antibodies in the early phase of the allergic reaction, as was shown in a decrease in skin reactivity [17] . the molar ratio of allergen specific IgE to IgG antibodies is of interest. To properly compare the amounts of allergen specific IgE and IgG the raw data (percentage binding) can not be compared (as is shown in Eig. I).
Although the sera tested and discussed in this paper are limited, the usage of these antibodies as a reference reagent is demonstrated. Like hIgE-Dp2 A [24] , chimeric hlgGl-Dp2 A and hIgG4-Dp2 A antibodies have several advantages in their use as reference serum compared to serum antibodies. The production by a hybridoma-like cell line provides unlimited access to well defined antibodies. The only immunoglobulin present in the culture supernatant is allergen specific IgGl or IgG4. Some light chain overexpression was observed; however, these light chains did not bind to the absorbent (data not shown). This panel of chimeric antibodies enables the quantification and comparison of isotype specific, antiallergen antibodies in sera.
